Similar articles

• Long-Term Safety of Tolvaptan in ADPKD: Where Do We Stand?

  Patel DM, Dahl NK. Patel DM, et al. Clin J Am Soc Nephrol. 2020 Dec 31;16(1):3-5. doi: 10.2215/CJN.17981120. Epub 2020 Dec 29. Clin J Am Soc Nephrol. 2020. PMID: 33376103 Free PMC article. No abstract available.
• Comparing Effects of Tolvaptan and Instruction to Increase Water Consumption in ADPKD: Post Hoc Analysis of TEMPO 3:4.

  Gobburu J, Ivaturi V, Wang X, Shoaf SE, Jadhav P, Perrone RD. Gobburu J, et al. Kidney360. 2023 Dec 1;4(12):1702-1707. doi: 10.34067/KID.0000000000000302. Epub 2023 Nov 21. Kidney360. 2023. PMID: 37986188 Free PMC article.
• Curative Effect and Safety of Tolvaptan Combined With Traditional Diuretics in Treatment of Patients With Cirrhotic Ascites and Relevant Research on Its Dose.

  Li X, Liu S, Xu H, Zhou W. Li X, et al. Am J Ther. 2023 Mar-Apr 01;30(2):158-162. doi: 10.1097/MJT.0000000000001327. Epub 2021 Jan 1. Am J Ther. 2023. PMID: 33416254 No abstract available.
• Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials.

  Urbach J, Goldsmith SR. Urbach J, et al. Ther Adv Cardiovasc Dis. 2021 Jan-Dec;15:1753944720977741. doi: 10.1177/1753944720977741. Ther Adv Cardiovasc Dis. 2021. PMID: 33435837 Free PMC article. Review.
• Tolvaptan for Volume Management in Heart Failure.

  Gunderson EG, Lillyblad MP, Fine M, Vardeny O, Berei TJ. Gunderson EG, et al. Pharmacotherapy. 2019 Apr;39(4):473-485. doi: 10.1002/phar.2239. Epub 2019 Apr 1. Pharmacotherapy. 2019. PMID: 30802995 Review.